101. High-dose therapy and bone marrow transplantation in cutaneous T-cell lymphoma.
- Author
-
Oyama Y, Guitart J, Kuzel TM, Burt RK, and Rosen ST
- Subjects
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Combined Modality Therapy, Female, Humans, Lymphoma, T-Cell, Cutaneous drug therapy, Male, Middle Aged, Remission Induction, Skin Neoplasms drug therapy, Transplantation, Autologous, Transplantation, Homologous, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bone Marrow Transplantation, Hematopoietic Stem Cell Transplantation, Lymphoma, T-Cell, Cutaneous therapy, Skin Neoplasms therapy
- Abstract
Although most patients who have cutaneous T-cell lymphoma have an indolent clinical course, patients who have cutaneous tumors, lymph node or visceral involvement, or peripheral blood involvement generally have rapidly progressive disease with shorter survival. In those patients with poor prognostic features, conventional combination chemotherapy is usually ineffective. High-dose chemotherapy with autologous hematopoietic stem cell transplant (HSCT) results in high remission rates, but the recurrence is inevitable and rapid. Allogeneic HSCT, in contrast, provides durable long-term remissions and is currently the only potentially curative therapy.
- Published
- 2003
- Full Text
- View/download PDF